Unicycive Therapeutics, Inc. (UNCY) Stock Ticker
UNCY right now
Market factors today
Unlock the full UNCY picture
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
UNCY stock facts
| Ticker symbol | UNCY |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $125.4M |
| CEO | Shalabh K. Gupta |
| Employees | 21 |
| Headquarters | Mountain View, CA, US |
| IPO date | 2021-07-12 |
| Website | www.unicycive.com |
What you can see for UNCY on Tickr
Live UNCY price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the UNCY report.
Rankings
FAQ
What is the ticker symbol for Unicycive Therapeutics, Inc.?
The ticker symbol for Unicycive Therapeutics, Inc. is UNCY, listed on the NASDAQ Capital Market.
What is UNCY?
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.